反馈咨询
欢迎添加微信!
微信号:z_gqing
微信二维码:
扫公众号
期刊文献 > Cancer Cell期刊 选择月份
2023 Sep (6)
2023 Aug (10)
2023 Jul (4)
2023 Jun (9)
2023 May (9)
2023 Apr (11)
2023 Mar (15)
2023 Feb (11)
2023 Jan (17)
2022 Dec (17)
2022 Nov (17)
2022 Oct (18)
2022 Sep (17)
2022 Aug (13)
2022 Jul (11)
2022 Jun (15)
2022 May (12)
2022 Apr (12)
2022 Mar (14)
2022 Feb (14)
2022 Jan (14)
2021 Dec (13)
2021 Nov (13)
2021 Oct (13)
2021 Sep (13)
2021 Aug (19)
2021 Jul (13)
2021 Jun (15)
2021 May (14)
2021 Apr (15)
2021 Mar (13)
2021 Feb (17)
2021 Jan (14)
1. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer.
Cancer Cell
2021 Jul 12
Hornburg M, Desbois M, Lu S
2. N(6)-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation.
Cancer Cell
2021 Jul 12
Cheng Y, Xie W, Pickering BF
3. Artificial intelligence for clinical oncology.
Cancer Cell
2021 Jul 12
Kann BH, Hosny A, Aerts HJWL.
4. Tim-4(+) cavity-resident macrophages impair anti-tumor CD8(+) T cell immunity.
Cancer Cell
2021 Jul 12
Chow A, Schad S, Green MD
5. The loss of RNA N(6)-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8(+) T cell dysfunction and tumor growth.
Cancer Cell
2021 Jul 12
Dong L, Chen C, Zhang Y
6. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.
Cancer Cell
2021 Jul 12
Joshi SK, Nechiporuk T, Bottomly D
7. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Cancer Cell
2021 Jul 12
Pusztai L, Yau C, Wolf DM
8. Cavity macrophages stop anti-tumor T cells.
Cancer Cell
2021 Jul 12
Rodriguez PC, Ruffell B.
9. Is glucose the scapegoat for tumor evasion?
Cancer Cell
2021 Jul 12
Raines LN, Huang SC.
10. Stepwise evolution of therapy resistance in AML.
Cancer Cell
2021 Jul 12
Gui P, Bivona TG.
11. Oncogenic mutations drive intestinal cancer initiation through paracrine remodeling.
Cancer Cell
2021 Jul 12
Yan HHN, Chan AS, Leung SY.
12. I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment.
Cancer Cell
2021 Jul 12
Perez-Garcia J, Gion M, Cortes J.
13. Learning from BISCAY: The future of biomarker-based trial design in bladder cancer.
Cancer Cell
2021 Jul 12
Meza L, Salgia NJ, Patel KC
Copyright © 2021-2024 上海牛马人生物科技有限公司 沪ICP备 2022007390号-2